Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DSCI

Derma Sciences (DSCI) Stock Price, News & Analysis

Derma Sciences logo

About Derma Sciences Stock (NASDAQ:DSCI)

Advanced Chart

Key Stats

Today's Range
$7.00
$7.00
50-Day Range
N/A
52-Week Range
$2.92
$7.05
Volume
N/A
Average Volume
719,592 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive DSCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Derma Sciences and its competitors with MarketBeat's FREE daily newsletter.

DSCI Stock News Headlines

Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio
Dermavant Sciences Ltd.
Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
See More Headlines

DSCI Stock Analysis - Frequently Asked Questions

Derma Sciences Inc (NASDAQ:DSCI) announced its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.16. The medical instruments supplier earned $22.20 million during the quarter, compared to analyst estimates of $22.40 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Derma Sciences investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Antares Pharma (ATRS) and Bellicum Pharmaceuticals (BLCM).

Company Calendar

Last Earnings
8/09/2016
Today
4/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:DSCI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:DSCI) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners